Literature DB >> 11920581

Cancer chemoresistance: the relationship between p53 and multidrug transporters.

Jason A Bush1, Gang Li.   

Abstract

Extensive studies indicate that both p53 and multidrug transporters play important roles in chemoresistance. Since the initial reports a decade ago demonstrating a transcriptional dependence of the ABCB1 gene (MDR) promoter by p53, much data have been accumulated. However, despite being the subject of intense study, this p53-MDR relationship remains unclear in human cancers. The data are confounded by variable and contrasting results when considering the in vitro regulation and attempting to draw parallels in tissue specimens. The original model suggested that wild-type p53 downregulates the ABCB1 promoter, whereas mutant p53 increases expression of ABCB1. This review summarizes the data for and against this hypothesis. What emerges from these studies is a complex picture, where data have been obtained in support of this hypothesis, but there are also many circumstances where it is not supported. Taken together, these data suggest that the relationship between p53 and multidrug transporters is conditional. It is dependent on cellular environment, the drug used, and the nature of the p53 mutation. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920581     DOI: 10.1002/ijc.10226

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  34 in total

1.  A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer.

Authors:  Jung Hun Oh; Joseph O Deasy
Journal:  Brief Bioinform       Date:  2015-07-27       Impact factor: 11.622

2.  Association of Two Polymorphic Codons in P53 and ABCC1 Promoter with Prostate Cancer.

Authors:  Farinaz Behfarjam; Jalal Rostamzadeh; Mohammad Ali Zarei; Bahram Nikkhoo
Journal:  Iran J Biotechnol       Date:  2015-03       Impact factor: 1.671

3.  MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling.

Authors:  Toshiyuki Sakaeda; Tsutomu Nakamura; Midori Hirai; Takashi Kimura; Atsushi Wada; Tatsurou Yagami; Hironao Kobayashi; Shunji Nagata; Noboru Okamura; Takayoshi Yoshikawa; Toshiro Shirakawa; Akinobu Gotoh; Masafumi Matsuo; Katsuhiko Okumura
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

Review 4.  AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.

Authors:  Bowen Yan; David Claxton; Suming Huang; Yi Qiu
Journal:  Exp Hematol       Date:  2020-06-20       Impact factor: 3.084

5.  Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.

Authors:  Kari J Brewer Savannah; Elizabeth G Demicco; Kristelle Lusby; Markus Ph Ghadimi; Roman Belousov; Eric Young; Yiqun Zhang; Kai-Lieh Huang; Alexander J Lazar; Kelly K Hunt; Raphael E Pollock; Chad J Creighton; Matthew L Anderson; Dina Lev
Journal:  Clin Cancer Res       Date:  2012-07-20       Impact factor: 12.531

Review 6.  Mutant p53: one name, many proteins.

Authors:  William A Freed-Pastor; Carol Prives
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

7.  Application of metasurface-enhanced infra-red spectroscopy to distinguish between normal and cancerous cell types.

Authors:  G Kelp; N Arju; A Lee; E Esquivel; R Delgado; Y Yu; S Dutta-Gupta; K Sokolov; G Shvets
Journal:  Analyst       Date:  2019-01-31       Impact factor: 4.616

8.  A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging.

Authors:  Long Gu; Walter M Tsark; Donna A Brown; Suzette Blanchard; Timothy W Synold; Susan E Kane
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-12       Impact factor: 11.205

9.  Effluxing ABC transporters in human corneal epithelium.

Authors:  Kati-Sisko Vellonen; Eliisa Mannermaa; Helen Turner; Marika Häkli; J Mario Wolosin; Timo Tervo; Paavo Honkakoski; Arto Urtti
Journal:  J Pharm Sci       Date:  2010-02       Impact factor: 3.534

Review 10.  When mutants gain new powers: news from the mutant p53 field.

Authors:  Ran Brosh; Varda Rotter
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.